Page 1 of Clinical Trials for ACZ885, 57 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Last Updated: April 9, 2012
Condition(s): Acute Gout
2
Completed
Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy
Last Updated: April 12, 2011
Condition(s): Gout
3
Recruiting
Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Last Updated: April 27, 2012
Condition(s): Gouty Arthritis
4
Completed
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
Last Updated: April 12, 2011
Condition(s): Rheumatoid Arthritis
5
Terminated
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
Last Updated: August 24, 2009
Condition(s): Rheumatoid Arthritis
6
Completed
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
Last Updated: June 28, 2011
Condition(s): Rheumatoid Arthritis
7
Recruiting
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Last Updated: April 10, 2012
Condition(s): Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease
8
Completed
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Last Updated: August 8, 2011
Condition(s): Arthritis, Juvenile Rheumatoid
9
Completed
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Last Updated: August 3, 2011
Condition(s): Type 2 Diabetes Mellitus; Impaired Glucose Tolerance
10
Recruiting
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Last Updated: May 7, 2012
Condition(s): Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease
11
Terminated
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
Last Updated: March 13, 2012
Condition(s): Systemic Juvenile Idiopathic Arthritis
12
Active, not recruiting
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Last Updated: April 14, 2012
Condition(s): Systemic Juvenile Idiopathic Arthritis
13
Completed
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Last Updated: May 23, 2012
Condition(s): Schnitzler Syndrome
14
Completed
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
Last Updated: January 10, 2012
Condition(s): Type 2 Diabetes Mellitus
15
Recruiting
Ilaris (Canakinumab) in the Schnitzler Syndrome
Last Updated: December 14, 2011
Condition(s): Schnitzler Syndrome
16
Active, not recruiting
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Last Updated: March 5, 2012
Condition(s): Type 1 Diabetes; Preservation of Insulin Secretion; Newly Diagnosed Type 1 Diabetes; Canakinumab in Type 1 Diabetes
17
Completed
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Last Updated: June 14, 2011
Condition(s): Cryopyrin-associated Periodic Syndromes:; Familial Cold Autoinflammatory Syndrome; Muckle Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease
18
Completed
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
Last Updated: February 8, 2008
Condition(s): Rheumatoid Arthritis
19
Active, not recruiting
Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Last Updated: July 7, 2011
Condition(s): Urticaria; Vasculitis
20
Recruiting
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Last Updated: May 3, 2012
Condition(s): Diabetes Mellitus, Type 2; Atherosclerosis; Prediabetic State

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=ACZ885

Page 1 of Clinical Trials for ACZ885, 57 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About